A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.
Abstract
Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.
참고문헌 (24)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.359~386 (2015)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Al-Batran SE, "Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin : a study of the Arbeitsgemeinschaft Internistische Onkologie", J Clin Oncol, 26, pp.1435~1442 (2008)
- Van Cutsem E, "Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the V325 Study Group", J Clin Oncol, 24, pp.4991~4997 (2006)
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Macdonald JS, "Gastric cancer : Nagoya is not New York", J Clin Oncol, 29, pp.4348~4350 (2011)
- Ohtsu A, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a randomized, double-blind, placebo-controlled phase III study", J Clin Oncol, 29, pp.3968~3976 (2011)
- Lordick F, "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND) : a randomised, open-label phase 3 trial", Lancet Oncol, 14, pp.490~499 (2013)
- Ohtsu A, "Everolimus for previously treated advanced gastric cancer : results of the randomized, double-blind, phase III GRANITE-1 study", J Clin Oncol, 31, pp.3935~3943 (2013)
- Ajani JA, "Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma", J Clin Oncol, 23, pp.6957~6965 (2005)
- Kim KM, "Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force", Asia Pac J Clin Oncol, 10, pp.297~307 (2014)
- Sawaki A, "Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer : a subgroup analysis of the Trastuzumab for Gastric Cancer(ToGA)study", Gastric Cancer, 15, pp.313~322 (2012)
- Kurokawa Y, "Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer(HERBIS-1)", Br J Cancer, 110, pp.1163~1168 (2014)
- Ryu MH, "Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer", Eur J Cancer, 51, pp.482~488 (2015)
- Koizumi W, "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial) : a phase III trial", Lancet Oncol, 9, pp.215~221 (2008)
- Lauren P., "The two histological main types of gastric carcinoma:diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification", Acta Pathol Microbiol Scand, 64, pp.31~49 (1965)
- Smalley SR, "Updated analysis of SWOG-directed intergroup study 0116 : a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection", J Clin Oncol, 30, pp.2327~2333 (2012)
- Qiu M, "Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients", BMC Cancer, 14, pp.823~ (2014)
- Hecht JR, "Lapatinib in combination with capecitabine plus oxaliplatin(CapeOx)in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma(AC) : The TRIO-013", LOGiC Trial, 2013, pp.31, ~
- Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, 357, pp.1810~1820 (2007)
- Satoh T, "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations : TyTAN : a randomized, phase III study", J Clin Oncol, 32, pp.2039~2049 (2014)
- Gomez-Martin C, "Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab", J Clin Oncol, 31, pp.4445~4452 (2013)
- Ock CY, "Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer", Clin Cancer Res, 21, pp.2520~2529 (2015)
- Lee HE, "Clinical significance of intratumoral HER2 heterogeneity in gastric cancer", Eur J Cancer, 49, pp.1448~1457 (2013)